n.a. (FURX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 10.82M
Div & Yield N.A. (N.A)
Furiex Pharmaceuticals To Present At Cowen & Company 33rd Annual Healthcare Conference

Furiex Pharmaceuticals To Present At Cowen & Company 33rd Annual Healthcare Conference

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, announced today that June Almenoff, M.

Furiex Receives Qualified Infectious Disease Product And Fast Track Designations From The U.S. Food And Drug Administration For Avarofloxacin (JNJ-Q2)

Furiex Receives Qualified Infectious Disease Product And Fast Track Designations From The U.S. Food And Drug Administration For Avarofloxacin (JNJ-Q2)

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced today that avarofloxacin (USAN adopted, INN approval pending), has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.

4 Stocks Spiking on Unusual Volume

4 Stocks Spiking on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

These 10  “Buy” Rated Stocks Have Significant Insider Buying Activity

These 10 “Buy” Rated Stocks Have Significant Insider Buying Activity

Looking to trade stocks that have positive ratings and bullish indicators? Consider the following list of 10 stocks (and 2 [...]

Furiex Pharmaceuticals Announces Fourth Quarter And Full Year 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Fourth Quarter And Full Year 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter and full year 2012 financial results on Wednesday, March 6, 2013, after the market closes.

Stocks Settle Mixed as Investors Take Breather

Stocks Settle Mixed as Investors Take Breather

Major U.S. stock averages trade mixed Monday after a substantial run-up in the benchmark indices the prior week.

Stock Futures Rise After Caterpillar, Durable Goods Reports

Stock Futures Rise After Caterpillar, Durable Goods Reports

Stock futures are rising Monday after a better-than-expected earnings report from Caterpillar and durable goods orders report.

Furiex Confirms Takeda’s Receipt Of FDA Approval Of NESINA (alogliptin) And Fixed-Dose Combinations OSENI (alogliptin And Pioglitazone) And KAZANO (alogliptin And Metformin HCl) For The Treatment Of Type 2 Diabetes

Furiex Confirms Takeda’s Receipt Of FDA Approval Of NESINA (alogliptin) And Fixed-Dose Combinations OSENI (alogliptin And Pioglitazone) And KAZANO (alogliptin And Metformin HCl) For The Treatment Of Type 2 Diabetes

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.

Furiex Pharmaceuticals Inc. Stock Upgraded (FURX)

Furiex Pharmaceuticals Inc. Stock Upgraded (FURX)

Furiex Pharmaceuticals (Nasdaq:FURX) has been upgraded by TheStreet Ratings from a sell to hold.

Furiex Reports Third Quarter 2012 Financial Results

Furiex Reports Third Quarter 2012 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2012.

Furiex Pharmaceuticals Announces Third Quarter 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Third Quarter 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its third quarter 2012 financial results on Thursday, November 1, 2012, after the market closes.

Furiex Reports Second Quarter 2012 Financial Results

Furiex Reports Second Quarter 2012 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended June 30, 2012.

Furiex Pharmaceuticals Amends Current Loan And Security Agreement, Adding An Additional $30.0 Million

Furiex Pharmaceuticals Amends Current Loan And Security Agreement, Adding An Additional $30.0 Million

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced today it has restructured its Loan and Security Agreement (Agreement) with MidCap Financial LLC and Silicon Valley Bank to add $30.

Furiex Pharmaceuticals Announces Closing Of Priligy® Asset Transfer And License Agreements

Furiex Pharmaceuticals Announces Closing Of Priligy® Asset Transfer And License Agreements

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced it has completed the closings under the previously announced Asset Transfer Agreement with ALZA Corporation and Janssen Pharmaceutica, NV (Janssen) for...

7 Stocks Rising on Unusual Volume

7 Stocks Rising on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Furiex Confirms Takeda’s Resubmissions Of Alogliptin And The Fixed-Dose Combination Alogliptin And Pioglitazone NDAs To The U.S. FDA

Furiex Confirms Takeda’s Resubmissions Of Alogliptin And The Fixed-Dose Combination Alogliptin And Pioglitazone NDAs To The U.S. FDA

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc.

Furiex Pharmaceuticals Announces Second Quarter 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Second Quarter 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its second quarter 2012 financial results on Thursday, August 2, 2012, after the market closes.

Furiex Pharmaceuticals Announces First Patient Dosed In Phase III Clinical Trials Of MuDelta In Diarrhea-Predominant Irritable Bowel Syndrome

Furiex Pharmaceuticals Announces First Patient Dosed In Phase III Clinical Trials Of MuDelta In Diarrhea-Predominant Irritable Bowel Syndrome

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta...

Furiex Confirms Takeda’s Announcement On The Acceptance Of The EMA Submissions For Two Fixed-Dose Alogliptin Combination Therapies For The Treatment Of Type 2 Diabetes

Furiex Confirms Takeda’s Announcement On The Acceptance Of The EMA Submissions For Two Fixed-Dose Alogliptin Combination Therapies For The Treatment Of Type 2 Diabetes

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Global Research & Development Centre (Europe) Ltd.

Insiders Trading END, HUTC, FURX, SNI

Insiders Trading END, HUTC, FURX, SNI

The top 10 open-market insider purchases and sales filed at the SEC Friday.

Insiders Trading HPQ, LNKD, FURX, CPRT

Insiders Trading HPQ, LNKD, FURX, CPRT

The top 10 open-market insider purchases and sales filed at the SEC Monday.

Insiders Trading FURX, DSW, PMTI, CTL

Insiders Trading FURX, DSW, PMTI, CTL

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

Insiders Trading CVI, FB, FURX, BLK

Insiders Trading CVI, FB, FURX, BLK

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

Furiex Confirms Takeda’s Announcement On The Acceptance Of The European Medicines Agency Submission Of Alogliptin For The Treatment Of Type 2 Diabetes

Furiex Confirms Takeda’s Announcement On The Acceptance Of The European Medicines Agency Submission Of Alogliptin For The Treatment Of Type 2 Diabetes

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Global Research & Development Centre (Europe) Ltd.

Furiex Pharmaceuticals And Menarini Announce License Agreement For Priligy®

Furiex Pharmaceuticals And Menarini Announce License Agreement For Priligy®

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) and Menarini Group today announced that they have entered into a license agreement by which Furiex will license to Menarini rights to commercialize Priligy® in Europe,...

Furiex Pharmaceuticals Announces Agreement To Transfer Priligy® Product Rights

Furiex Pharmaceuticals Announces Agreement To Transfer Priligy® Product Rights

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced that it has entered into an agreement with ALZA Corporation and Janssen Pharmaceutica, N.

Furiex Reports First Quarter 2012 Financial Results

Furiex Reports First Quarter 2012 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended March 31, 2012.

Furiex Pharmaceuticals Inc. Stock Downgraded (FURX)

Furiex Pharmaceuticals Inc. Stock Downgraded (FURX)

Furiex Pharmaceuticals (Nasdaq:FURX) has been downgraded by TheStreet Ratings from from a hold to sell.

Furiex Stock Gaps Down On Today's Open (FURX)

Furiex Stock Gaps Down On Today's Open (FURX)

Shares of Furiex Pharmaceuticals (Nasdaq:FURX) were gapping down Thursday morning with an open price 27.3% lower than Wednesday's closing price. The stock closed at $19.60 yesterday and opened today's trading at $14.24.

Furiex Confirms Takeda’s Receipt Of Complete Response Letter From The FDA For Alogliptin And Fixed-Dose Combination Alogliptin And Pioglitazone

Furiex Confirms Takeda’s Receipt Of Complete Response Letter From The FDA For Alogliptin And Fixed-Dose Combination Alogliptin And Pioglitazone

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda has received a complete response letter from the U.